Date: 2017-08-21
Type of information: Development agreement
Compound: novel biologic therapies including TAK-671
Company: Samsung Bioepis (Republic of Korea) Takeda Pharmaceutical (Japan)
Therapeutic area: Inflammatory diseases
Type agreement: development - collaboration
Action mechanism:
Disease: acute pancreatitis, undisclosed diseases
Details:
- • On August 21, 2017, Samsung Bioepis announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas.
- The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.
The risk-sharing partnership brings together Samsung Bioepis’ agile biologics development platform with Takeda’s best-in-class experts in drug development to co-fund and collaboratively develop innovative therapies representing meaningful value to patients who need them. Additional terms of the collaboration are not being disclosed.
Since its establishment in 2012, Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, has developed a broad pipeline of biosimilar candidates (Flixabi®/Renflexis®, Imraldi®, Brenzys™/Benepali™, SB3 , SB8 (bevacizumab), SB9/insulin glargine). The company now intends to develop original products. Takeda becomes its first development partner and Samsung Bioepis will also seek another partners.
Financial terms:
Latest news:
Is general: Yes
